Edwyn
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $40,479 | $42,440 | $49,954 | $52,961 | $57,399 |
| Gross Profit | $15,213 | $10,926 | $13,093 | $15,353 | $17,678 |
| Operating Income | $15,213 | $10,926 | $13,093 | $15,353 | $17,678 |
| Net Income | $13,746 | $6,717 | $8,503 | $10,467 | $12,443 |
Over the period from 2021 to 2025, Oracle’s financials show an overall upward trajectory in revenue, gross profit, operating income, and net income, despite a notable dip in 2022. Revenue increased from $40.5 billion in 2021 to nearly $57.4 billion by 2025, reflecting steady top-line growth. However, 2022 stands out as an anomaly: despite a revenue increase to $42.4 billion, gross profit fell sharply from $15.2 billion to $10.9 billion, and net income plummeted from $13.7 billion to approximately $6.7 billion. This significant year-over-year swing (well over a 20% change) suggests that the company might have faced rising operational expenses or one-off expenses impacting its margins during that year. Following 2022, Oracle appears to have corrected its course, with all key metrics rebounding. By 2023, revenue climbed to roughly $50 billion, and gross profit, operating income, and net income all exhibited healthy growth, continuing through 2024 and 2025. The consistent improvement across operating and net profitability indicates efficient management controls and an ability to adapt to evolving market conditions in the highly competitive enterprise software and cloud computing space. Overall, these metrics suggest that despite the setbacks experienced in 2022, Oracle is sustaining financial health and operational resilience. Continued improvements in revenue and profit generation position the company well for industry sustainability and long-term investor confidence.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.